Clarus Therapeutics Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRXTQ research report →
About the company
Clarus Therapeutics Holdings, Inc. is a pharmaceutical enterprise dedicated to developing and marketing oral testosterone replacement therapies across the United States. Its primary offering is JATENZO, an oral soft gel formulation of testosterone undecanoate, prescribed for men suffering from hypogonadism.
- CEO
- Robert E. Dudley
- IPO
- 2021
- Employees
- 16
- HQ
- Northbrook, IL, US
Price Chart
- Market Cap
- $72.83K
- P/E
- -0.02
- P/S
- 0.00
- P/B
- -0.07
- EV/EBITDA
- -0.64
- Div Yield
- 0.00%
- Gross Margin
- 80.51%
- Op Margin
- -177.13%
- Net Margin
- -404.90%
- ROE
- -462.78%
- ROIC
- -88.56%
- Revenue
- $13.96M · 119.14%
- Net Income
- $-56,512,000 · -411.47%
- EPS
- $-8.04 · -1476.47%
- Op Income
- $-39,732,000
- FCF YoY
- -5.21%
- 52W High
- $3.94
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.14
- Beta
- 1.68
- Avg Volume
- 117.01K
Get TickerSpark's AI analysis on CRXTQ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our CRXTQ coverage
Recent articles, reports, and earnings notes.
No research on CRXTQ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CRXTQ report →Similar companies
Peers in the same neighborhood.